Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway

Blood

Volumn 112, Issue 12, 2008, Pages 4765-4775

  Mariotti, Jacopo ^a   Foley, Jason ^a   Ryan, Kaitlyn ^a   Buxhoeveden, Nicole ^a   Kapoor, Veena ^a   Amarnath, Shoba ^a   Fowler, Daniel H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; STAT6 PROTEIN; STAT1 PROTEIN; STAT1 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD DONOR; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL THERAPY; CELL TRANSFER; CELL TYPE; CYTOKINE RELEASE; ENGRAFTMENT; FEMALE; GRAFT REJECTION; HOST CELL; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE; TH1 CELL; TH2 CELL; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; GENETICS; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; ISOGRAFT; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR; TH1 CELLS; TH2 CELLS; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 58149382715     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-154278     Document Type: Article

References (45)

1. Gale RP, Reisner Y. Graft rejection and graft-versus-host disease: mirror images. Lancet. 1986;1:1468-1470.
2. Bennett M, Kumar V, Mikhael A, et al. Rejection of bone marrow cells by irradiated mice: NK and T cells recognize different antigens. Transplant Proc. 1987;19:5-11.
3. Korngold B, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med. 1978;148:1687-1698.
4. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood. 1994;84:3540-3549.
5. Krenger W, Snyder KM, Byon JC, Falzarano G, Ferrara JL. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol. 1995;155:585-593.
6. Foley JE, Jung U, Miera A, et al. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J Immunol. 2005;175:5732-5743.
7. Vallera DA, Taylor PA, Sprent J, Blazar BR. The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation. 1994; 57:249-256.
8. Graubert TA, Russell JH, Ley TJ. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood. 1996; 87:1232-1237.
9. Baker MB, Podack ER, Levy RB. Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice. Biol Blood Marrow Transplant. 1995;1:69-73.
10. Zimmerman Z, ShatryA, DeyevV, etal. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways. Biol Blood Marrow Transplant. 2005;11:576-586.
11. Mariotti J, Foley J, Jung U, et al. Ex vivo rapamycin generates apoptosis-resistant donor th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection. J Immunol. 2008;180:89-105.
12. Gur H, Krauthgamer R, Berrebi A, et al. Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells. Blood. 2002;99:4174-4181.
13. Bachar-Lustig E, Reich-Zeliger S, Reisner Y. Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose. Blood. 2003;102:1943-1950.
14. Jung U, Foley JE, Erdmann AA, Eckhaus MA, Fowler DH. CD3/CD28- costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVTand GVHD effects. Blood. 2003;102:3439-3446.
15. Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J Exp Med. 1993;178:703-712.
16. LapidotT, Lubin I,TerenziA, Faktorowich Y, Erlich P, Reisner Y Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity. Proc Natl Acad Sci USA. 1990;87:4595-4599.
17. Martin PJ. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism. Blood. 1996;88:962-969.
18. Hiruma K, Nakamura H, Henkart PA, Gress RE. Clonal deletion of postthymic T cells: veto cells kill precursor cytotoxic T lymphocytes. J Exp Med. 1992;175:863-868.
19. Reich-Zeliger S, Bachar-Lustig E, Gan J, Reisner Y Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. I. Relative reactivity of different veto cells. J Immunol. 2004;173:6654-6659.
20. Reich-Zeliger S, Zhao Y, Krauthgamer R, Bachar-Lustig E, Reisner Y Anti-third party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity. 2000;13: 507-515.
21. Reich-Zeliger S, Gan J, Bachar-Lustig E, Reisner Y. Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. II. Deletion of effector cells by Fas-Fas ligand apoptosis. J Immunol. 2004;173:6660-6666.
22. Martin PJ, Akatsuka Y, Hahne M, Sale G. Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection. Blood. 1998;92:2177-2181.
23. Fowler DH, Whitfield B, Livingston M, Chrobak P Gress RE. Non-host-reactive donor CD8+ T cells of Tc2 phenotype potently inhibit marrow graft rejection. Blood. 1998;91:4045-4050.
24. Erdmann AA, Jung U, Foley JE, Toda Y, Fowler DH. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection. Biol Blood Marrow Transplant. 2004;10:604-613.
25. Taylor PA, Panoskaltsis-Mortari A, Swedin JM, et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood. 2004; 104:3804-3812.
26. Hanash AM, Levy RB. Donor CD4 + CD25 + T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood. 2005;105:1828-1836.
27. Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med. 1990;172:921-929.
28. Labeur MS, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol. 1999;162:168-175.
29. Kaplan MH, Sun YL, HoeyT, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature. 1996;382:174-177.
30. Wang HY, Paul WE, Keegan AD. IL-4 function can be transferred to the IL-2 receptor by tyrosine containing sequences found in the IL-4 receptor alpha chain. Immunity. 1996;4:113-121.
31. Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest. 2000;105:1289-1298.
32. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000;100:655-669.
33. Afkarian M, Sedy JR, Yang J, et al. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol. 2002;3:549-557.
34. Qin S, Cobbold SP, Pope H, et al. "Infectious" transplantation tolerance. Science. 1993;259: 974-977.
35. Quigley M, Huang X, Yang Y. STAT1 signaling in CD8 T cells is required for their clonal expansion and memory formation following viral infection in vivo. J Immunol. 2008;180:2158-2164.
36. TakedaA, Hamano S, YamanakaA, et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol. 2003;170:4886-4890.
37. Holschermann H, StadlbauerTH, Wagner AH, et al. STAT-1 andAP-1 decoy oligonucleotide therapy delays acute rejection and prolongs cardiac allograft survival. Cardiovasc Res. 2006;71: 527-536.
38. Akalin E, Hancock WW, Perico N, et al. Blocking cell microtubule assembly inhibits the alloimmune response in vitro and prolongs renal allograft survival by inhibition ofTh1 and sparing of Th2 cell function in vivo. J Am Soc Nephrol. 1995;5:1418-1425.
39. Siegling A, Lehmann M, Riedel H, et al. Anondepleting anti-rat CD4 monoclonal antibody that suppresses T helper 1-like but not T helper 2-like intragraft lymphokine secretion induces long-term survival of renal allografts. Transplantation. 1994; 57:464-467.
40. Zhu J, Min B, Hu-Li J, et al. Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat Immunol. 2004;5:1157-1165.
41. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202:907-912.
42. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4 + CD25 + FoxP3 + regulatory T cells. Blood. 2005;105:4743-4748.
43. Wei J, Duramad O, Perng OA, Reiner SL, Liu YJ, Qin FX. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc Natl Acad Sci USA. 2007;104:18169-18174.
44. Zimmerman ZF, Levy RB. MiHA reactive CD4 and CD8 T-cells effect resistance to hematopoietic engraftment following reduced intensity conditioning. Am J Transplant. 2006;6:2089-2098.
45. Higuchi M, Zeng D, Shizuru J, et al. Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NKT cells and clonal deletion. J Immunol. 2002;169:5564-5570.